Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(17):1246; doi:10.1093/jnci/dji299
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Appell, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Appell, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Maine Law Requires Drug Companies To Provide Clinical Trial Data

David Appell

The first 10% of the full text of this article appears below.

A new state law in Maine promises to increase disclosure of clinical trials sponsored by drug companies, providing a first-in-the-nation look at all clinical trial data for every drug on the market.

The law, which goes into effect in mid-October, will provide patients and doctors with unprecedented access to the data resulting from drug clinical trials, including harmful side effects that often remain hidden from public view.

"Responses have been very positive," said Arthur Lerman, the Maine state representative who sponsored the bill. "People are eager . . . [Full Text of this Article]

Implementing the Law

Duplication of Effort?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?